Swiss National Bank Reduces Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Swiss National Bank lowered its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 10.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 400,600 shares of the biopharmaceutical company’s stock after selling 47,000 shares during the quarter. Swiss National Bank’s holdings […]

Related Keywords

Switzerland ,Swiss ,Michaelw Bonney , ,Alnylam Pharmaceuticals ,Bessemer Group Inc ,Quarter For Alnylam Pharmaceuticals ,First Capital Advisors Group ,Jpmorgan Chase Co ,Alnylam Pharmaceuticals Company Profile ,Capital Advisors Ltd ,Cantor Fitzgerald ,Nasdaq ,Swiss National Bank ,Kb Financial Partners ,News Ratings For Alnylam Pharmaceuticals Daily ,Alnylam Pharmaceuticals Stock Performance ,Alnylam Pharmaceuticals Inc ,V Square Quantitative Management ,Free Report ,National Bank ,Square Quantitative Management ,Director Michael ,Visit Holdingschannel ,Alnylam Pharmaceuticals Daily ,Nasdaq Alny ,Dalny ,Medical ,02043q10 ,Sec Filings ,13f ,Hedge Fund Holdings ,Institutional Investor Holdings ,